A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512
Completed · Phase 3
Conditions studied: Dry Eye Disease
In brief
The purpose of this study is to evaluate the safety of topical ophthalmic 0.003% AR-15512 compared to its vehicle dosed twice daily (BID) in subjects with dry eye disease (DED) for 12 months.
Key facts
- Study ID
- NCT05493111
- Run by
- Aerie Pharmaceuticals
- People needed
- 275
- Starts
- 2022-11-01
- Expected to finish
- 2024-02-28
- Last updated by the study team
- 2025-08-13
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Arizona Eye Center — Chandler, Arizona, United States
- Arizona Eye Institute — Sun City, Arizona, United States
- Global Research Management — Glendale, California, United States
- Macy Eye Center — Los Angeles, California, United States
- Eye Research Foundation — Newport Beach, California, United States
- Shultz Vision — Northridge, California, United States
- SightMD — Manhasset, New York, United States
- University Eye Specialists — Maryville, Tennessee, United States
- Piedmont Eye Center — Lynchburg, Virginia, United States
- Periman Eye Institute — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.